Hormone therapy linked to positive changes in appearance congruence, mental health for transgender and nonbinary youthJanuary 23rd 2023
In what investigators are calling the largest study of its kind ever conducted in the US, results of the 2-year study, which included more than 300 transgender or nonbinary youth, underline the positive benefits seen with receipt of gender-affirming hormone therapy among this patient population.
Study raises concerns over increasing BMI, obesity in preschool-aged children during pandemicJanuary 5th 2023
Using data from more than 25,000 preschool-aged children in Sweden provides an overview in trends of weight gain and BMI changes that may have impacted pediatric populations during the COVID-19 pandemic.
FDA approves teplizumab for delay of type 1 diabetes in patients 8 years and upNovember 18th 2022
The US FDA announced the approval of teplizumab (Tzield), which is administered through IV infusion once daily for 14 consecutive days, for delaying the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes.